Lung cancer and pleural mesothelioma are often confused, so it’s important to understand the key differences between them, including tumor location and treatments. Lung cancer and pleural mesothelioma ...

Malignant pleural mesothelioma continues to be a challenge. The diagnosis and treatment of patients with malignant pleural mesothelioma requires a multidisciplinary approach. The diagnosis is best ...

August 31, 2009 — Pleural fluid mesothelin is a helpful adjunct to cytology examination in patients with an undiagnosed pleural effusion, according to the results of a study reported in the September ...

NovoTTF-100L System, combined with chemotherapy, is FDA-approved for malignant pleural mesothelioma, marking the first new treatment in over 15 years. The STELLAR trial showed a median overall ...

The combination statistically significantly improved overall survival, reducing the risk of death by 21% compared with chemotherapy alone. The Food and Drug Administration (FDA) has approved Keytruda ...

Malignant pleural mesothelioma is a refractory tumor with poor prognosis associated with asbestos exposure. Pleural effusion is frequently observed in patients with malignant pleural mesothelioma, and ...

Please provide your email address to receive an email when new articles are posted on . Access to care varied significantly among patients with stage I to stage III malignant pleural mesothelioma, ...

CHICAGO — The addition of nintedanib to pemetrexed/cisplatin appeared safe and effective for the treatment of patients with malignant pleural mesothelioma, according to results from the LUME-Meso ...

Nobody likes to talk or think about cancer, but it’s a serious disease that we should all aim to understand a little better. Better understanding the signs and symptoms of cancer, as well as how to ...

Dr. Hedy Kindler joins us on the podcast to discuss the latest update to the treatment of pleural mesothelioma guideline. She discusses the latest changes to the updated recommendations across topics ...

Worldwide Trends in the Epidemiologic Features of Malignant Mesothelioma. In addition to its substantial personal and health care costs, malignant mesothelioma is associated with compensation costs ...

American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor ...